Cordycepin

Cordycepin, also known as 3'-deoxyadenosine, is a nucleoside analogue produced by certain fungi, most notably Cordyceps militaris and related species. It is structurally similar to adenosine but lacks the 3'-hydroxyl group on the ribose sugar. This modification gives cordycepin distinctive biochemical properties and makes it a subject of interest as a natural product and as a research compound in pharmacology and molecular biology. It can be obtained from cultured Cordyceps strains or through fermentation processes.

In cells, cordycepin is phosphorylated to its monophosphate, diphosphate, and triphosphate forms. The triphosphate form can be incorporated into RNA by RNA polymerases in place of ATP, leading to premature termination of RNA chains due to the absence of a 3'-OH group necessary for chain elongation. This mechanism underlies observed effects on RNA synthesis and has been linked to cytotoxic activity in cancer cell lines. Cordycepin has also demonstrated antiviral, anti-inflammatory, and anti-proliferative effects in various preclinical models, though results vary and are predominantly limited to in vitro or animal studies.

Clinical considerations and safety: There are no approved medical uses for cordycepin in humans, and robust clinical evidence is lacking. Its activity is influenced by metabolic processes such as deamination by adenosine deaminase and by cellular kinases that govern phosphorylation. Cordycepin-containing products may interact with adenosine signaling pathways or nucleoside metabolism, raising potential safety concerns, particularly with other nucleoside therapies or adenosine-modulating drugs. Further research and controlled clinical trials are needed to establish safety, dosing, and efficacy.